logo
  

Lululemon Athletica Lifts FY Outlook

While reporting its third quarter results, Lululemon Athletica Inc. (LULU) lifted its outlook for the full year.

Looking forward to the full year, the yoga apparel retailer now expects adjusted earnings of $7.69 to $7.76 per share and revenues of $6.25 billion to $6.29 billion.

Previously, the company expected adjusted earnings of $7.38 to $7.48 per share and revenues of $6.19 billion to $6.26 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $7.51 per share and revenues of $6.27 billion.

Meghan Frank, Chief Financial Officer, stated: "Our teams continue to execute at a high level, which has enabled our strong Q3 performance and the upward revision to our guidance. We are pleased with these results given the ongoing, industry-wide supply chain issues we continue to navigate. While there are several large volume weeks ahead of us, we feel well positioned for a strong end to 2021."

For the fourth quarter, the company expects adjusted earnings of $3.25 to $3.32 per share and revenues of $2.125 billion to $2.165 billion. Analysts currently estimate earnings of $3.30 per share on revenues of $2.17 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
RELATED NEWS
Follow RTT